Needham Reiterates Buy on Cogent Biosciences, Maintains $18 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia reiterated a Buy rating on Cogent Biosciences (NASDAQ:COGT) and maintained an $18 price target.
May 08, 2024 | 9:56 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Ami Fadia reiterated a Buy rating on Cogent Biosciences and maintained an $18 price target.
The reiteration of a Buy rating and maintenance of an $18 price target by a reputable analyst like Ami Fadia from Needham is likely to instill confidence in investors about Cogent Biosciences' potential, potentially leading to a positive short term impact on the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100